Atea Pharmaceuticals (AVIR) AGM 2026 summary

Opening remarks and agenda

• Meeting commenced with introductions of board members and executive team, including representatives from the independent auditor KPMG.

• Stockholders were informed of meeting procedures, voting eligibility, and rules of conduct.

Board and executive committee updates

• Three Class III directors were nominated for re-election to serve until 2029.

• Board and executive team members were introduced, highlighting leadership continuity.

Shareholder proposals

• Proposals included election of directors, ratification of KPMG as auditor for 2026, and advisory approval of executive compensation.